Charles Schwab
GLUE icon

Charles Schwab’s Monte Rosa Therapeutics GLUE Stock Holding History

Charles Schwab’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.9M Buy
616,310
+69,621
+13% +$1.32M ﹤0.01% 1971
2026
Q1 		$8.99M Buy
546,689
+97,975
+22% +$1.87M ﹤0.01% 2152
2025
Q4 		$7.04M Buy
448,714
+65,446
+17% +$882K ﹤0.01% 2300
2025
Q3 		$2.84M Buy
383,268
+1,931
+0.5% +$10.2K ﹤0.01% 2663
2025
Q2 		$1.72M Buy
381,337
+19,802
+5% +$88.3K ﹤0.01% 2716
2025
Q1 		$1.68M Sell
361,535
-8,937
-2% -$54.8K ﹤0.01% 2670
2024
Q4 		$2.57M Buy
370,472
+23,974
+7% +$180K ﹤0.01% 2603
2024
Q3 		$1.84M Buy
346,498
+34,698
+11% +$175K ﹤0.01% 2733
2024
Q2 		$1.17M Buy
311,800
+61,218
+24% +$312K ﹤0.01% 2873
2024
Q1 		$1.77M Buy
250,582
+5,020
+2% +$29.8K ﹤0.01% 2629
2023
Q4 		$1.39M Buy
245,562
+3,069
+1% +$12K ﹤0.01% 2723
2023
Q3 		$1.16M Buy
242,493
+12,275
+5% +$79K ﹤0.01% 2753
2023
Q2 		$1.58M Buy
230,218
+5,832
+3% +$37.7K ﹤0.01% 2629
2023
Q1 		$1.75M Sell
224,386
-98
-0% -$681 ﹤0.01% 2562
2022
Q4 		$1.71M Buy
224,484
+11,269
+5% +$93.9K ﹤0.01% 2617
2022
Q3 		$1.74M Buy
213,215
+96,981
+83% +$891K ﹤0.01% 2619
2022
Q2 		$1.12M Sell
116,234
-9,166
-7% -$92.1K ﹤0.01% 2745
2022
Q1 		$1.76M Buy
125,400
+40,338
+47% +$560K ﹤0.01% 2689
2021
Q4 		$1.74M Buy
85,062
+5,088
+6% +$107K ﹤0.01% 2743
2021
Q3 		$1.78M Buy
+79,974
New +$2.29M ﹤0.01% 2725

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Charles Schwab's GLUE Position: Q2 2026 in Review

Charles Schwab increased its Monte Rosa Therapeutics (GLUE) stake by 13% in Q2 2026, buying an estimated $1.32M and bringing the position to 616,310 shares worth $14.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1971.

Charles Schwab first reported a position in GLUE in Q3 2021 and has held it in 20 quarters since. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Charles Schwab held 616,310 shares of Monte Rosa Therapeutics worth $14.9M as of Q2 2026.
  • Charles Schwab bought 69,621 Monte Rosa Therapeutics shares in Q2 2026, an estimated $1.32M.
  • Monte Rosa Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1971 holding.
  • Charles Schwab first reported a position in Monte Rosa Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.